Pharmaceuticals
Tonix Pharmaceuticals to Present Real-World Data on Fibromyalgia Treatment at ISPOR 2026
Tonix Pharmaceuticals will present findings from a retrospective cohort study on fibromyalgia treatment patterns using U.S. claims data, offering insights into real-world usage following the launch of its newly approved drug TONMYA.
SureNano Science Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
SureNano Science Ltd. and its subsidiary GlucaPharm Inc. are highlighted for developing GEP-44, a novel triple agonist peptide targeting the expanding GLP-1 market for obesity and metabolic disorders.
Oncotelic Therapeutics Doses First Patient in Phase 1b Trial of Sapu003 for Advanced Solid Tumors
Oncotelic Therapeutics and Sapu Nano announced the first patient dosed in a Phase 1b trial of Sapu003, an IV formulation of everolimus, aiming to improve delivery and reduce toxicity for advanced mTOR-sensitive solid tumors.
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
The rising prevalence of obesity and type 2 diabetes is driving significant interest in next-generation GLP-1 therapies, with companies like SureNano Science Ltd. developing novel triple agonists that could improve efficacy and tolerability in a rapidly expanding market.
Oncotelic’s Intranasal Brain Delivery Platform Highlighted as CNS Drug Development Gains Urgency
Oncotelic Therapeutics featured in BioMedWire editorial for its nose-to-brain delivery platform that bypasses the blood-brain barrier, with rising Alzheimer’s cases and biodefense needs driving demand for such technologies.
Tonix Pharmaceuticals to Present at Two Investor Conferences in May 2026
Tonix Pharmaceuticals announced its participation in the RBC Capital Markets Global Healthcare Conference and A.G.P.’s Annual Virtual Healthcare Conference, highlighting its commercial-stage pipeline and recent approval of TONMYA for fibromyalgia.
OS Therapies Gains Regulatory Clarity for OST-HER2 in Osteosarcoma, Stonegate Capital Reports
Stonegate Capital Partners updates coverage on OS Therapies, highlighting EMA rolling review and TGA endpoint alignment that shift OST-HER2 toward a global approval pathway, with key survival data catalysts in 2026.
SureNano Science’s GLP-1 Triple Agonist GEP-44 Targets Obesity Market as Next-Generation Therapies Gain Traction
SureNano Science Ltd. is highlighted in a BioMedWire editorial for its subsidiary GlucaPharm’s GEP-44 triple agonist peptide, which aims to improve efficacy, tolerability, and delivery flexibility in the growing GLP-1 market for obesity and metabolic diseases.
Tonix Pharmaceuticals Reports Q1 2026 Results, Highlights TONMYA Commercial Growth and Pipeline Progress
Tonix Pharmaceuticals reported Q1 2026 financial results, showing early commercial success for its fibromyalgia drug TONMYA and advancing pipeline candidates including a Lyme disease prevention therapy.
SureNano Science Launches IND-Enabling Program for Obesity and Diabetes Drug GEP-44, Targeting a $200 Billion Market
SureNano Science has initiated an FDA-aligned GLP toxicology and pharmacology program for its lead candidate GEP-44, a multi-receptor peptide for obesity and type 2 diabetes, positioning the company to enter the rapidly growing GLP-1 market projected to reach $200 billion by 2030.
Oncotelic Therapeutics Advances Pipeline Without Dilution Through Partnership Strategy
Oncotelic Therapeutics is using a partnership-driven approach and its deep IP portfolio to advance its pipeline without shareholder dilution, as highlighted in a corporate update.
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Kairos Pharma Sets Virtual Annual Meeting, Discloses Going Concern Notice
Kairos Pharma announced its virtual annual meeting and disclosed a going concern notice in its 2025 annual report, highlighting financial uncertainties for the clinical-stage biopharmaceutical company.
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.
SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44
SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide for improved GLP-1 therapy, aiming to address obesity and diabetes alongside major players like Eli Lilly and Novo Nordisk.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Tonix Pharmaceuticals Secures GPO Agreement Covering 35 Million Lives for TONMYA Fibromyalgia Treatment
Tonix Pharmaceuticals announced a group purchasing organization agreement effective May 1, 2026, covering approximately 35 million U.S. commercial lives for its FDA-approved non-opioid fibromyalgia treatment TONMYA, expanding patient access.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
CNS Pharmaceuticals Raises $22.5 Million to Advance Pipeline and Corporate Strategy
CNS Pharmaceuticals announced a $22.5 million private placement with institutional investors to fund asset acquisition and working capital, signaling a strategic push to expand its pipeline.
NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks
NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting regulatory advancement as global cases rise.
Carmed Pharmaceuticals Launches 'Farkındayım' Initiative Ahead of U.S. Expansion
Carmed Pharmaceuticals launches a social impact initiative where digital engagement with music and video directly funds animal welfare, signaling a purpose-driven brand strategy as it expands into the U.S. market.
Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Alignment with Executive Order on Mental Health
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions while reaffirming the collaboration's support for Phase 3 recruitment in major depressive disorder and alignment with a recent executive order on mental health treatments.
BioVersys Shareholders Approve All Board Proposals, Including New Board Member and Compensation Packages
BioVersys AG announced that shareholders approved all board proposals at its annual general meeting, including the re-election of directors and election of a new board member, as the company advances its lead antibiotic candidate into Phase 3 trials.
Oncotelic Therapeutics Advances AI and Robotics Platform Toward Initial Commercial Deployment
Oncotelic Therapeutics reports progress on its proprietary AI platform and robotics integration, aiming to improve efficiency and compliance in pharmaceutical development and manufacturing.
Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.